Source:http://linkedlifedata.com/resource/pubmed/id/11511925
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2001-8-20
|
| pubmed:abstractText |
By decreasing plasminogen binding to fibrin surface, the thrombin activatable fibrinolysis inhibitor (TAFI) has been hypothesized to constitute an early marker for atherothrombotic diseases. Previous studies have shown that plasma TAFI levels exhibit a high interindividual variability that is only poorly explained by lifestyle factors. Several polymorphisms of the TAFI gene have been described, and a combination of a C+1542G substitution in the 3' untranslated region and an Ala147Thr amino acid change has been shown to explain 60% of TAFI variability in a sample of unrelated individuals. A segregation-linkage analysis was performed to determine whether these polymorphisms are directly involved in the genetic regulation of TAFI levels, or whether they are only markers in linkage disequilibrium (LD) with unmeasured TAFI-linked quantitative trait loci (QTLs). The sample consisted of 97 healthy nuclear families from the Stanislas Cohort. The C+1542G and Ala147Thr polymorphisms were in complete negative LD, with minor allele frequencies of 0.27 and 0.28, respectively. Results of the segregation-linkage analysis provided evidence of two TAFI-linked QTLs in LD with the two measured polymorphisms, which would explain 78% of the TAFI variance, as compared with 55% explained by the C+1542G and the Ala147Thr polymorphisms combined. The two putative QTLs would have minor allele frequencies of 0.45 and 0.32, respectively. The hypothesis that one of the measured polymorphisms is one of the QTLs was rejected. The putative QTLs also did not seem compatible with the other TAFI gene polymorphisms that we have previously described. More extensive sequencing of the TAFI gene is necessary to identify the functional variants.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0340-6717
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
109
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
191-7
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:11511925-Adolescent,
pubmed-meshheading:11511925-Adult,
pubmed-meshheading:11511925-Carboxypeptidase U,
pubmed-meshheading:11511925-Carboxypeptidases,
pubmed-meshheading:11511925-Child,
pubmed-meshheading:11511925-Chromosome Segregation,
pubmed-meshheading:11511925-Female,
pubmed-meshheading:11511925-Gene Frequency,
pubmed-meshheading:11511925-Genetic Linkage,
pubmed-meshheading:11511925-Genotype,
pubmed-meshheading:11511925-Haplotypes,
pubmed-meshheading:11511925-Humans,
pubmed-meshheading:11511925-Linkage Disequilibrium,
pubmed-meshheading:11511925-Lod Score,
pubmed-meshheading:11511925-Male,
pubmed-meshheading:11511925-Polymorphism, Genetic,
pubmed-meshheading:11511925-Polymorphism, Single Nucleotide,
pubmed-meshheading:11511925-Quantitative Trait, Heritable
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms.
|
| pubmed:affiliation |
INSERM U525, Epidemiological and Molecular Genetics of Cardiovascular Diseases, 91 bd de l'Hôpital, 75634 Paris Cedex 13, France, Paris. tregouet@idf.inserm.fr
|
| pubmed:publicationType |
Journal Article
|